From the Journals

ICYMI: Dabigatran no better than aspirin for recurrent stroke prevention


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran was slightly but not significantly superior to aspirin at the prevention of recurring stroke in patients with a recent history of embolic stroke of undetermined source over a median follow-up of 19 months (6.6% rate of recurrent stroke for dabigatran vs. 7.7% for aspirin; hazard ratio, 0.85; 95% confidence interval, 0.69-1.03; P = 0.10), according to RE-SPECT ESUS, a multicenter, randomized, double-blind trial published in the New England Journal of Medicine (2019 May 15. doi: 10.1056/NEJMoa1813959).

We first reported on the results of this trial when they were presented at the World Stroke Congress by lead investigator Hans-Christoph Diener, MD. Find our coverage at the link below.

Next Article: